DISCO Pharmaceuticals is an oncology biotech leveraging a proprietary platform that maps the entire cell surface (the surfaceome) to uncover novel target pairs for drug development. Using these discoveries, the company engineers highly selective bispecific antibody-drug conjugates (ADCs) and T-cell engagers aimed at indications such as small cell lung cancer and microsatellite-stable colorectal cancer. The technology is designed to broaden the universe of actionable cancer targets and improve therapeutic precision. Recently, DISCO appointed veteran oncology executive Mark Manfredi, Ph.D., as CEO, while founder Roman Thomas, M.D., transitioned to a strategic advisor role. With a total of €36 million in seed capital, the company plans to move multiple lead ADC candidates into IND-enabling studies and to expand both indication-specific and pan-tumor programs. Investors believe the platform can unlock entirely new therapeutic areas by revealing previously unknown cell-surface biology. The fresh capital provides runway to advance the lead programs toward the clinic and continue generating additional surfaceome-based targets.

Total raised

$64M

Funding rounds

2

Latest round

Seed

Latest activity

Dec 2025